Skip to main content

DICYNONE

DICYNONE 



****** Result for Image/Page 1 ******
DICYNONE AMPOULES
Antihemorrhagic
Composition
DICYNONE
Each 2 m; arnpoule contains: diethylammonium I .4 dihydroxybenzenesuifonate (INN, etamsylate) 250 mg,
antiox. (E 223) 08 mg.
Each tablet contains: diethylammonium I ,4 dihydroxybenzenesulfonate (INN, etamsylate) 250 mg.
DICYNONE 500
Each tablet contains: diethylammonium I dihydroxybenzenesulfonate (INN, etamsylate) 500 mg.
antiox. (E 221).
Properties / Mode of action
Etamsy!3te is a synthetic antihernorrhagjc and angioprotective drug acting on the first step of hemostasis
(endothelium - platelet interaction). BV improving platelet adhesiveness and restonng capillary resistance, it
reduces (he bleedinq time and blood fosses. Etamsylate has no vasoconstrictor action , it does not influence
tibrinotysis nor modify the plasma coagulation factors.
Pharmacokinetics
After i.v. administration of 500 mg etamsylate, the maximum plasma level, i.e. 50 pg / ml, is reached at
10 minutes. The plasma half-life is around 1 ,9 h. About 85% oi the administered dose are excreted in the first
24 h -urine.
When given po . etamsylate is resorbed through the gastrointestinal tract. After oral administration of
500 mg etarnsvtate, maximum plasma level, i.e. 15 ug/rnl, is reached at 4 h. The plasma half-life IS around
3,7 h. About 720/0 of the administered dose are excreted in the first 24 h-urine; the molecule is excreted
unchanged.
Etamsylate crosses the placentai barrier. Materna! and cord blood contains similar concentrations of
etamsyiate.
Indications
In surgery: Prevention and treatment of per- or postsurgical oozing in all delicate operations and in those
affecting highly vascularized tissues: E.N.T, gynecology, obstetrics, urology, odontostomatology, ophthal-
mology, plastic and reconstructive surgery.
In intemal medicine: Prevention and treatment of capillary hemorrhages of whatever origin or localization;
hematuria, hematemesis, melena, metrorrhagia, primary or IUD-related menorrhagia , epistaxis, gingivorr-
hagia.
in pediatrics: Prevention of periventricular hemorrhages in premature babies.
DCYNONE
Adults:
Presurgical: 1-2 ampoules i.v. or i.m. 1 hour before surgery.
Persurgical: 1-2 ampoules i.v. Repeat the dosage if necessary.
Postsurgtcal: 1-2 ampoules (1-2 tablets). Repeat every 4-6 hours as long as the bleeding risk persists.
Emergency cases, according to the severity of the case:l -2 ampoules i.v. or i.m. Repeat every 4-6 hours as
long as the risk of bleeding persists.
Local treatment: soak a swab with the content of an ampoule and apply to hemorrhagic area, or in the tooth
socket after dental extraction. The application may be repeated when necessary; it may be associated with
oral or parenterai administration.
Children: halt the adult dose.
Pediatrics: 10 mg per kg body weight (0.1 ml-12.5 mg) injected intramuscularly wtthin 2 hours atter birth
then every 6 hours for 4 days.
DICYNONE 500
Adults:
Postsurgjcal: I tablet, repeat every 4-6 hours as long as the bleeding risk persists,
Internal medicine generally, 2-3 tablets daily; the duration of treatment depends on the results.
Gynecology, in meno-metrorrhagia: from the fifth day before the expected onset of the menstrua' period
3 tablets da.ly for 10 days.
Children: half the adult dose.
umitations for use - As for most drugs, Dicynone!Dicynone 500 Should not be taken during the first
trimester of pregnancy.
Adverse effects - Etamsyiate does not induce serological or allergic side-effects.
Interactidt* - Dicynone/Dicynone 500 may be given In association with any other drug (for example anti-
coagulants). When a perfusion with dextran is necessary. Dicynone has to be administered first.
Stability - Protect the ampoules from light. Discard Dicynone ampoules if the solution is coloured.
Dtcynone/Dlcynone 500 may be administered until the expiration date indicated on the package (EXP).
Presentations
DICYNONE
Ampoules (250 mg/2 ml): 3 , 100
0M 0M Laboratories Ltd, Meyrin-Geneva (Switzerland)

Comments

Popular posts from this blog

SPASMO - DIGESTIN

SPASMO   -   DIGESTIN   Digestant, Choleretic,   Enteric Coated Tablets Spasmolytic and   Antiflatulent   —   Composition:   Each tablet contains   Papain 100mg — -.“ -. Sanzyme 3500 .36 mg   Sodium delrydrochotate 10mg   Dicyclomine hydrochloride 5mg   Simethicorre 30 mg   Properties:   Spasmo - dlgsstin is a well balanced combination with specific digestivecholeretic.   spasmolytic and antillatulent properties. Spasmo - digestin provides the body with   papain, the proteolytic enzyme, in addition to sanzyme 3500 which is a rnuttienzyme   complex containing mainly protease, amyfase. tipase and cellulase.These enzymes act   upon food contents of the GIT and catalyze their conversion into simpler and easily   digestible and absorbable components. Spasmo - digestin therefore brings to   completion hydrolysis of protems into peptones and small peptides; &tarch into dextrins   ...

FLUMOX

FLUMOX Composition: Each dosage unit contains Amonycillirr (as trihydrate) Capsule 250mg 125mg   125mg Flaclosacillin (as monofrydrate)   Amonycillin (as sodium salt)   Flucloxacillin (as Sodium salt) 500mg 250mg   250mg 5mI Susp. 250mg   125mg   125mg Vll5 500mg 250mg   250mg ig   500mg   500mg Properties:   FLUMOX®   isa combination of two bactericidal penicillins: amoxycilin (broadspectwm penicillin) and flucloxacillin (penicillinase-resistant penicillin), to produce a wider spectrum of ac5vity. Flucloxacillin exerts a bactericidal action on penicillinase -producing microorganism including most staphylococci.This combination exhibits bactericidal activity against a wide range of Gram-positive and Gram-negative microorganisms including   penicillinase and 41 on peniciiinase   -   producing Staphylococci, Streptococcus pyogenes, pneumoniae, and faecalis, Corynebacterillm diphtheria...

Epimag

Epimag For The Medical Profession Only EPIMAG® Effervescent Powder Composition: Each 5 gm sachet contains: Magnesium citrate 2.125 g Properties: Magnesium ions inhibit formation of calcium oxalate crystals by combination with exogenous dietatric oxalate thus preventing formation of renal crystalluria. The citrate ions render urine alkaline so that urates may dissolve and are easily eliminated. Also, citrate ions, by chelating calcium ions, inhibit formation of calcium oxalate. Therefore, magnesium citrate may be prescribed to prevent recurrence of calcium oxalate kidney stones. Magnesium citrate is an osmotic laxative. Pharmacokinetics: Oral magnesium salts, including citrate, are generally very slowly absorbed from the gastrointestinal tract. They are excreted rapidly in the urine (absorbed fraction) and the faeces (unabsorbed fraction). Indications: • Cases of oxaluria. • Mild laxative to relieve constipation. Dosage and Administration: The contents of o...